Provided by Tiger Fintech (Singapore) Pte. Ltd.

iBio

0.6590
-0.0210-3.09%
Post-market: 0.65910.0001+0.02%17:40 EDT
Volume:371.33K
Turnover:245.17K
Market Cap:10.69M
PE:-0.28
High:0.6922
Open:0.6800
Low:0.6479
Close:0.6800
Loading ...

iBio Faces Nasdaq Delisting Notice for Stock Price

TIPRANKS
·
31 mins ago

iBio Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Requirement

Reuters
·
1 hour ago

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
25 Jun

iBio, AstralBio unveil obesity program with amylin receptor agonist antibody

TIPRANKS
·
24 Jun

BRIEF-Ibio And Astralbio Unveil Obesity Program With Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

Reuters
·
24 Jun

iBio Inc. Announces Extension of Promissory Note with Safi Biotherapeutics, Requires Interest Payment for Extension

Reuters
·
18 Jun

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
17 Jun

BRIEF-IBio Initiates Non-Human Primate Study Of First-In-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention In Weight Regain After GLP-1 Treatment

Reuters
·
16 Jun

iBio initiates non-human primate study of IBIO-610

TIPRANKS
·
16 Jun

IBio Files Prospectus for Resale of About 11.3 Million Shares

MT Newswires Live
·
13 Jun

Vaccine Stocks Surge with Moderna up 11%

Tiger Newspress
·
20 May

Trump Says He Will Cut Drug Prices by 59%

Reuters
·
12 May

iBio Is Maintained at Buy by Chardan Capital

Dow Jones
·
05 May

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

GlobeNewswire
·
05 May

iBio, Inc. Reports Strong Q3 2025 Progress

TIPRANKS
·
05 May

BRIEF-iBio Reports Fiscal Third Quarter 2025 Financial Results

Reuters
·
02 May

iBio Q3 EPS $(0.49) Misses $(0.34) Estimate

Benzinga
·
02 May

Press Release: iBio Reports Fiscal Third Quarter 2025 Financial Results

Dow Jones
·
02 May

BRIEF-Ibio Inc Enters Exclusive License Agreement With AstralBio

Reuters
·
23 Apr

iBio Enters Licensing Agreement for Obesity Treatment

TIPRANKS
·
23 Apr